Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer
April 14th 2020Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.
Read More
Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity
April 13th 2020Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II OVARIO trial.
Read More
Following its success in the phase III PRIMA study, frontline niraparib maintenance demonstrated positive patient-reported outcomes, as well as met biomarker-defined and other secondary endpoints, according to 3 analyses to be reported as part of the Society of Gynecologic Oncology 2020 Annual Meeting.
Read More
Careful Data Review Recommended for Upfront Treatment Selection in iNHL
February 29th 2020To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.
Read More
R-CHOP Still Chosen Over Targeted Therapies in Frontline DLBCL
February 29th 2020In an interview with Targeted Oncology, Jason Westin, MD, MS, FACP, discussed the pros and cons of administering R-CHOP in the frontline setting of diffuse large B-cell lymphoma. He also discussed other options for patients who have limited responses to the standard-of-care.
Read More
Strategic Management of CAR T-cell AEs in Hematologic Malignancies
February 29th 2020For patients receiving chimeric antigen receptor T-cell therapy, cytokine release syndrome and neurotoxicity are the most common toxicities. A multidisciplinary approach to care is vital for these patients, explained Kimberly Noonan, DNP, ANP-BC, AOCN, in a presentation during the 24th Annual International Congress on Hematologic Malignancies.
Read More
New Data May Significantly Improve Options for Myelofibrosis Therapy Following Ruxolitinib Failure
February 28th 2020At the 24th Annual International Congress on Hematologic Malignancies, host by Physicians’ Education Resourceâ, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.
Read More
Novel Agents Continue to Advance in the Treatment Landscape of DLBCL
February 28th 2020Because diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in the US, clinical investigators are eager to make progress with novel agents, despite recent advances, said Craig Moskowitz, MD, in a presentation during the 2020 International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma.<br />
Read More
Existing CAR T Cells Show Promise Even as Newer Agents Emerge in Multiple Myeloma
February 28th 2020In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.
Read More
Narsoplimab Shows Promise in Treating Posttransplant Complications
February 23rd 2020Evolving data about possible therapeutic targets for the treatment of transplant-associated thrombotic microangiopathy may introduce narsoplimab as a new therapy for management of patients with this challenging complication.
Read More
Evaluation of an expansion cohort of the pivotal phase I/II ZUMA-1 trial in patients with refractory large B-cell lymphoma revealed that early steroid intervention may have a positive impact on the toxicity profile of chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel, according to findings presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More
Favorable Safety and Efficacy May Be Possible With Off-the-Shelf CAR T Cells in NHL
February 22nd 2020Use of an off-the-shelf chimeric antigen receptor T-cell product may be feasible for use in patients with relapsed/refractory B-cell malignancies for whom no other available therapies exist, according to results of a phase I trial in adult and pediatric patients that were presented at the 2020 Transplant & Cellular Therapies Meeting in Orlando, Florida.
Read More
CAR T-Cell Therapy With Liso-Cel in the Outpatient Setting Reported as Safe and Effective
February 21st 2020Outpatient treatment with lisocabtagene maraleucel had consistent efficacy and safety with that of a previously reported clinical trial involving patients who were treated at university medical centers, according to results of 3 studies reported at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More
Factors Affecting Hemopoietic Recovery in Patients Following CAR T-Cell Therapy
February 21st 2020In an interview with Targeted Oncology at the 2020 Transplantation & Cellular Therapy Meetings, Craig Sauter, MD, discussed the retrospective real-world review of patients with hematologic malignancies who developed cytopenia post-chimeric antigen receptor T-cell therapy.
Read More
Ruxolitinib Observed To Be Safe, Effective for Treating Chronic GVHD in Different Patient Subsets
February 20th 2020Treating chronic graft-versus-host disease with ruxolitinib in both adult and pediatric patients was found to be safe and effective based on data from 2 separate single-center retrospective analyses whose results were presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More
Patients With Metastatic RCC Receive TKIs or mTOR Inhibitors After Immunotherapy
February 18th 2020Most patients with metastatic renal cell carcinoma whose disease progresses after immunotherapy given either alone or in combination with other agents receive subsequent treatment with VEGF tyrosine kinase inhibitors or mTOR inhibitors. When administered post-immunotherapy, cabozantinib is associated with superior median progression free survival, according to retrospective data from a real-world study of patients treated at 16 Italian referral centers.
Read More
Effects of SBRT Plus Nivolumab Result in Responses for Certain RCC Subgroups
February 17th 2020Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma, according to lead investigator Cristina Masini, MD, who presented the data at the 2020 Genitourinary Cancers Symposium.
Read More
Nivolumab Plus Sitravatinib Combo Impresses in Renal Cell Carcinoma
February 17th 2020Combining a broad-spectrum tyrosine kinase inhibitor with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma.
Read More
MK-6482 Active in Advanced Clear Cell RCC
February 16th 2020A fourth of patients with advanced clear cell renal cell carcinoma responded to single-agent therapy with an oral hypoxia-inducible factor–2α inhibitor, which achieved a disease control rate of 80%, a preliminary clinical trial showed.
Read More
Potential With Cabozantinib Plus Nivolumab in Advanced RCC
February 15th 2020Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
Watch
Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma
February 15th 2020Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Watch
Apalutamide Reduces Rate of Second Progression in Men With mCSPC
February 14th 2020Apalutamide plus androgen deprivation therapy reduced the risk of second progression or death regardless of hormonal or taxane therapy as the first subsequent life-prolonging therapy in patients with metastatic castration-sensitive prostate cancer.
Read More
Favorable, But Perplexing Results Observed, With Combination for mCRPC
February 14th 2020Men with metastatic castration-resistant prostate cancer had inferior immune responses with the combination of sipuleucel-T and radium-223 but improved clinical outcomes as compared with sipuleucel-T alone, a small randomized trial showed.
Read More